Brief: Ascendis Pharma A/S - Announces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia
30/06/2026 13:43
BRIEF-Ascendis Pharma A/S - Announces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia June 30 (Reuters) - Ascendis Pharma A/S A71.F:
ASCENDIS PHARMA A/S - ANNOUNCES WEEK 104 DATA FROM APPROACH TRIAL OF TRANSCON CNP IN CHILDREN WITH ACHONDROPLASIA
ASCENDIS PHARMA A/S - TRANSCON CNP SHOWS CONTINUED IMPROVEMENTS IN LOWER EXTREMITY ALIGNMENT THROUGH TWO YEARS OF TREATMENT
Source text: ID:nGNXcgGcHM
Further company coverage: A71.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascendis Pharma A/S
See all newsAscendis Pharma tumbles on Novo Nordisk collab termination
BioMarin climbs on global patent settlement with Ascendis
Brief: Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At Isds 2026
Brief: Eyconis Announces Initiation Of First-In-Human Clinical Trial Of Eyc-0305 In Treatment-Naïve Wet Age-Related Macular Degeneration Patients
Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary